Biogen (BIIB) Q3 2026 earnings review
Biogen's new drugs lift sales, but deal costs cut profit
Biogen's newly bought medicines drove a double-digit revenue gain while its older business barely grew. Total sales rose 11% from a year ago, but excluding the Apellis deal closed in May, sales from businesses owned a year ago edged up 1% by our math. Profit per share excluding one-offs fell 46% on an upfront research charge for buying RayThera, though chief executive Christopher A. Viehbacher nudged the bottom of the full-year earnings plan higher.
| Sales from businesses owned a year ago | +1.1% reported revenue: +10.6% from a year ago |
|---|---|
| Acquired Apellis drugs (Syfovre and Empaveli) | $242.8M +16.7% from their Q2 full-quarter pace |
| Profit per share, excluding one-offs | $2.62 -45.5% from a year ago (includes $284M deal charge) |
| Full-year profit per share outlook | Raised low end $0.20 $12.20–13.00, middle down 17.5% from 2025 |
⚖️ Verdict: 🟢 Bullish
The story got better because the Apellis drugs beat their pre-deal pace in their first full quarter and high-dose switches lifted Spinraza, cutting the acquisition's expected 2026 earnings drag by $0.30 per share. One caution: management kept its full-year revenue forecast at mid-single-digit growth, which by our math implies underlying sales outside Apellis will shrink in the fourth quarter.
The question now is whether Biogen's newer medicines can grow total revenue once the one-time boost from the Apellis purchase and Spinraza loading doses fades. Either the new launches and December's lupus trial readouts build a self-sustaining growth engine, or ongoing multiple sclerosis losses pull total revenue back to flat next year. Fourth-quarter sales and the December Phase 3 lupus results will settle it.
🐂 Bull Case
Apellis Drugs Beat Their Pre-Deal Pace
Biogen closed its purchase of Apellis Pharmaceuticals in May, adding two immunology medicines: Syfovre, an eye injection for geographic atrophy, and Empaveli, a treatment for rare kidney and blood disorders. This third quarter was their first full three months inside the biotechnology group. Together they brought in $242.8 million, beating the $208 million full-quarter pace they set in the second quarter by 16.7%.
- Syfovre sales: $191.3 million, up 27% from Apellis's prior-year quarter, with volume up 18%
- Empaveli sales: $51.5 million, up 92% from a year ago on kidney disease demand
- Expected 2026 earnings drag from Apellis: cut to $0.55 per share from $0.85 in July
The company noted Syfovre saw "commercial injections reaching their highest quarterly level since launch". Better sales and integration progress allowed finance chief Robin Kramer's team to trim the deal's expected full-year profit drag by $0.30 per share, while booking $66.5 million in restructuring charges.
What to watch: fourth-quarter combined sales for Syfovre and Empaveli. Another sequential gain would show that Biogen's commercial changes are driving durable volume rather than a one-time post-close bounce.
Higher Doses Lifted Spinraza and Rare Disease
Spinraza, a treatment for the muscle-wasting disorder spinal muscular atrophy, is converting patients to a new high-dose regimen approved earlier this year. Biogen said "Accelerated conversion to high-dose regimen continues to exceed Company expectations across all launched markets". Total Spinraza sales rose 23.2% from a year ago to $460.6 million, led by a 60.8% jump in the United States to $246.4 million.
Rare disease revenue grew 26.8% to $676.3 million. Skyclarys, a pill for the nervous-system disorder Friedreich's ataxia, rose 34.1% to $178.2 million, helped by demand and US inventory build, while ALS drug Qalsody grew 42.0% to $37.5 million. Because switching patients to high-dose Spinraza gives Biogen a one-time extra loading dose before regular maintenance resumes, part of the US surge is temporary, and sales outside the US slipped 3.0%.
What to watch: US Spinraza revenue in the first quarter of 2027, when initial patient switches slow down. Holding near current levels would show the higher dose is winning new patients.
Newer Drugs Outgrew the Multiple Sclerosis Decline
Even without the acquired Apellis medicines, Biogen's newer products grew fast enough to beat the decline in its older multiple sclerosis (MS) franchise. By our math, the growth portfolio excluding Apellis rose 20.7% from a year ago to $1,021.1 million, adding $175.2 million in revenue. That beat the $142.2 million drop across the entire MS line, which fell 13.4% to $919.3 million as generics hit Tecfidera and US formulary pressure hurt Vumerity.
Leqembi, the Alzheimer's antibody sold with partner Eisai, reached $202 million in global sales, up 66.9% from a year ago, with US sales of $107 million. Biogen booked $68.4 million as its share of the collaboration, up 60.2%. Zurzuvae, a pill for postpartum depression, rose 52.6% to $84.4 million.
What to watch: Leqembi US sales in the fourth quarter, the first full period for the at-home injector Iqlik. Faster US growth would show the easier injector is removing clinic bottlenecks.
🐻 Bear Case
Acquired Drugs Carried Almost All the Sales Gain
"Our third quarter results demonstrate that Biogen has returned to growth," chief executive Christopher A. Viehbacher said, pointing to an 11% rise in total revenue to $2,804.1 million. That headline figure includes a "strong first full quarter contribution from the acquired Apellis products", which had zero revenue in Biogen's prior-year numbers. Stripping out the $242.8 million from Syfovre and Empaveli, sales from businesses owned a year ago rose 1.1% by our math.
The company's full-year outlook points to a step back in the fourth quarter. Management kept its forecast for full-year revenue to grow by a mid-single-digit percentage, or about 5%. Because revenue is already up 5.3% through nine months, hitting 5% for the year leaves fourth-quarter total revenue up 3.9% by our math. If the Apellis drugs merely repeat their third-quarter sales, underlying revenue outside Apellis would fall about 6.8% in the fourth quarter.
What to watch: whether management raises the full-year revenue outlook or beats it in the fourth quarter. Landing near the 5% target would confirm that the business outside Apellis is still shrinking.
Deal Charges and Trial Costs Cut Profit in Half
Higher revenue did not reach the bottom line because deal charges and operating expenses grew much faster than sales. Profit per share excluding one-offs fell 45.5% from a year ago to $2.62, and Biogen recorded a GAAP net loss of $20.6 million. The biggest weight was $283.8 million in upfront research charges, "primarily related to the acquisition of RayThera Inc.", which took 10.1% of revenue.
- Research and development (excluding one-offs): $567.1 million, up 3.2 percentage points of revenue to 20.2%
- Selling and administrative (excluding one-offs): $729.7 million, up 2.7 percentage points of revenue to 26.0%
- Operating margin (excluding one-offs): 20.7% by our math, down 14.7 percentage points from 35.4% a year ago
Even adding back the RayThera charge, profit per share was $4.52 by our math, down from $4.81 a year ago. Bringing Apellis's staff and sales force onboard, funding late-stage clinical trials, and paying higher interest on acquisition debt absorbed the gross profit from the new medicines.
What to watch: full-year 2027 operating expense plans when fourth-quarter results arrive. That outlook will show how quickly the promised $250 million in Apellis cost savings will lower the spending base.
Pipeline Readouts and Unanswered Risks
Biogen's long-term case rests on clinical trials that begin reading out in weeks, while several standing business risks received no update in the earnings release. Management narrowed the timeline for its first major test, setting the Phase 3 readouts for lupus drug litifilimab in the first half of December 2026.
- Phase 3 lupus trials (TOPAZ-1 and TOPAZ-2): results due in the first half of December 2026, followed by skin lupus and transplant rejection readouts in the first half of 2027
- US pharmaceutical import tariffs: no update in the release on 2027 cost exposure for drugs made abroad; the quarterly filing will show any changes
- Litigation and tax: $26.6 million in new legal charges this quarter, while the RayThera charge pushed the GAAP tax rate to negative 128.5%
What to watch: the TOPAZ-1 and TOPAZ-2 topline announcement in early December. Positive results in both trials would validate the late-stage pipeline that management has built the company's story around.
💲 Other KPIs
Free cash flow — operating cash flow minus factory equipment purchases — fell 51.0% from $1,226.3 million a year ago on higher operating costs and working capital needs. Biogen still used the cash to pay down $400 million of short-term debt, lowering net debt from $6.80 billion in June to $6.39 billion.
Money owed by customers rose 40.4% from $1,342.4 million at the end of 2025, outpacing the 10.6% rise in quarterly revenue. Adding Apellis's specialty pharmacy billings and higher US sales of Spinraza and Skyclarys tied up more cash in unpaid invoices this quarter.
The share count used for profit per share excluding one-offs rose 1.3% from 147.1 million a year ago. Treasury stock on the balance sheet stayed unchanged at $2,977.1 million, showing the drugmaker again bought back no shares as it directs cash toward debt repayment and research deals.
🔮 Guidance
Raised. Biogen lifted the bottom of the range by $0.20, putting the middle at $12.60, down 17.5% from 2025. The company cited "ongoing business strength and Apellis dilution favorability", cutting the Apellis drag by $0.30 while adding $0.20 of research deal charges. Across four quarters, the middle of the range moved -$1.00, -$2.25, and +$0.10. By our math, the plan leaves $2.81 for the fourth quarter, up 41.2% against an easy prior-year comparison.
Unchanged. The plan still calls for full-year sales to grow about 5% from $9,890.6 million in 2025. Because revenue is already up 5.3% through the first nine months, a 5% full-year finish leaves fourth-quarter revenue up about 3.9% from a year ago by our math, down from 10.6% growth in the third quarter.
Unchanged. Management gave a full-year figure of $4.95 billion, up 19.2% from $4.15 billion in 2025 as Apellis operations and clinical trial costs roll in. With $3,545.5 million spent in the first nine months, the target leaves $1,404.5 million for the fourth quarter by our math — up 21.4% from a year ago, and matching the $2.70 billion second-half ceiling set in July.
❓ Key Questions
How much did the one-time loading dose lift US Spinraza?
US Spinraza revenue jumped 60.8% on high-dose switches, which include an extra loading dose before regular maintenance starts. Without the dollar split between loading doses and new patients, investors cannot tell how much revenue will repeat in 2027.
Why does the revenue plan imply a fourth-quarter slowdown?
Keeping the full-year revenue forecast at mid-single-digit growth implies fourth-quarter sales growth drops to about 3.9%, or a 6.8% decline outside Apellis by our math. Did management leave the outlook conservative, or will contract manufacturing and shipments fall?
How many patients started on the Leqembi at-home injector?
The subcutaneous injector Iqlik was due in the US market by late August, and US Leqembi sales rose $10 million from the second quarter to $107 million. The release gave no prescription or clinic adoption numbers for the new device.
What is the 2027 cost exposure from US drug tariffs?
Empaveli, Leqembi, Tecfidera and Vumerity are made mostly outside the United States. The release did not quantify the 2027 margin impact from the 100% US tariff on imported patented medicines once current domestic inventory runs out.